First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.

MLA

Avisar, Noa, et al. “First-in-Human, Phase I/IIa Dose-Escalation and Safety Study of Balugrastim in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy.” Cancer Chemotherapy and Pharmacology, vol. 75, no. 5, May 2015, pp. 929–39. EBSCOhost, https://doi.org/10.1007/s00280-015-2703-1.

APA

Avisar, N., Adar, L., Bock, J., Müller, U., Shen, D., Barash, S., & Pukac, L. (2015). First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. Cancer Chemotherapy and Pharmacology, 75(5), 929–939. https://doi.org/10.1007/s00280-015-2703-1

Chicago

Avisar, Noa, Liat Adar, Jason Bock, Udo Müller, David Shen, Steve Barash, and Laurie Pukac. 2015. “First-in-Human, Phase I/IIa Dose-Escalation and Safety Study of Balugrastim in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy.” Cancer Chemotherapy and Pharmacology 75 (5): 929–39. doi:10.1007/s00280-015-2703-1.